TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

TOBRADEX ST

DEXAMETHASONE Corticosteroid Hormone Receptor Agonists
Immunology Approved 2009-02-13
1
Indication
--
Phase 3 Trials
17
Years on Market

Details

Status
Prescription
First Approved
2009-02-13
Routes
OPHTHALMIC
Dosage Forms
SUSPENSION/DROPS

Companies

Active Ingredient: DEXAMETHASONE , TOBRAMYCIN

TOBRADEX ST Approval History

Loading approval history...

What TOBRADEX ST Treats

4 indications

TOBRADEX ST is approved for 4 conditions since its original approval in 2009. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Inflammatory Ocular Conditions
  • Bacterial Ocular Infection
  • Chronic Anterior Uveitis
  • Corneal Injury
Source: FDA Label
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

TOBRADEX ST FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

TOBRADEX ST ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical...

TOBRADEX ST Patents & Exclusivity

Latest Patent: Aug 2028

Patents (3 active)

US7795316 Expires Aug 3, 2028
US8101582 Expires Dec 19, 2027
US8450287 Expires Dec 19, 2027
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.